Your browser doesn't support javascript.
loading
Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?
Tokgoz, Husnu; Turkolmez, Kadir; Resorlu, Berkan; Kose, Kenan; Tulunay, Ozden; Beduk, Yasar.
Afiliación
  • Tokgoz, Husnu; University School of Medicine. Departments of Urology, Biostatistics and Pathology. Ankara. TR
  • Turkolmez, Kadir; University School of Medicine. Departments of Urology, Biostatistics and Pathology. Ankara. TR
  • Resorlu, Berkan; University School of Medicine. Departments of Urology, Biostatistics and Pathology. Ankara. TR
  • Kose, Kenan; University School of Medicine. Departments of Urology, Biostatistics and Pathology. Ankara. TR
  • Tulunay, Ozden; University School of Medicine. Departments of Urology, Biostatistics and Pathology. Ankara. TR
  • Beduk, Yasar; University School of Medicine. Departments of Urology, Biostatistics and Pathology. Ankara. TR
Int. braz. j. urol ; 33(6): 777-784, Nov.-Dec. 2007. graf, tab
Article en En | LILACS | ID: lil-476641
Biblioteca responsable: BR1.1
ABSTRACT

OBJECTIVE:

Compare clinical outcomes in patients having urothelial tumors invading less than one half of the depth of bladder muscle and greater than one half of bladder muscle and, to determine various clinical variables as predictive factors for survival. MATERIALS AND

METHODS:

According to our inclusion criteria, 57 patients among cases with T2 bladder tumor were selected. Thirty-five patients (61.4 percent) had pT2a (Group-1) and 22 patients (38.6 percent) had pT2b (Group-2) muscle invasive tumors. Mean follow up time was 7.3 years for Group-1, and 6.1 years for Group-2. Multivariate analysis was performed in order to identify possible correlation of clinical variables like age, gender, grade of primary tumor, appearance of local and/ or distant metastasis with patient outcome.

RESULTS:

Five year recurrence-free and overall survival rates were 69.1 percent and 44.3 percent for patients with pT2a tumor, whereas these ratios were 66.1 percent and 43 percent, respectively for patients with pT2b tumor (p = 0.896; p = 0.975). Mean overall and progression-free survival times were 87.7 ± 13.8 and 116 ± 13.12 months for Group-1, while they were 73.8 ± 13.7 and 88.85 ± 12.55 months for Group-2, respectively. On both univariate and multivariate analysis, age was noticed as an independent predictive factor for survival.

CONCLUSIONS:

The depth of muscle invasion in bladder tumors has no prognostic significance. Recurrence of the disease either locally or at distant sites dramatically shortens patients' life. Being older than 60 years old during the time of radical surgery, is also a bad prognostic factor for overall and progression-free survival.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 01-internacional Base de datos: LILACS Asunto principal: Vejiga Urinaria / Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales / Músculo Liso Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Int. braz. j. urol Asunto de la revista: UROLOGIA Año: 2007 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Brasil
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 01-internacional Base de datos: LILACS Asunto principal: Vejiga Urinaria / Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales / Músculo Liso Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Int. braz. j. urol Asunto de la revista: UROLOGIA Año: 2007 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Brasil